NIFTY® (Non-Invasive Fetal Trisomy) is a prenatal DNA test. The free DNA of the fetus, circulating in the maternal blood, is then analyzed to determine the health status of the baby. This analysis, very precise, safe for the mother and the fetus, measures the risk of trisomies: 21, 18 and 13 with a rate of sensitivity and accuracy of more than 99% *. We also offer additional tests for some number abnormalities of all fetal chromosomes, including sex chromosomes. The test can be performed as early as the 10th week of pregnancy, regardless of whether it is a single pregnancy, twin, or fetal resorption (one of the twins died in-utero). This type of analysis is recommended by the SOGC (Society of Obstetrics Gynecology of Canada) to avoid an invasive collection of amniocentesis (1). Talk to your doctor about whether the NIFTY® test is right for you.
There are two options for NIFTY® screening:
The NIFTY® option offered from the 10th week of pregnancy for a single or twin pregnancy. For a singleton pregnancy this option includes analysis of chromosome abnormalities , and microdeletions (83). For a twin pregnancy this includes trisomy 13,18 and 21.
The NIFTYPRO® option is also available from the 10th week of pregnancy for a single pregnancy. This option includes analysis of chromosomal abnormalities, microdeletions and DiGeorge syndrome.
*In the case of sex determination (possible in singleton and twin pregnancy) – this must be specified by the health professional on the medical prescription.
NIFTY® is now available directly at your home or workplace, appointments are available day, evening and weekend **. Travel costs to your location apply and are calculated based on distance traveled. Contact us directly at 1-888-PROCREA for more information and to make an appointment.
Prenatal Screening Comparisons
Find a NIFTY sampling center:
*For more information, please visit: http://www.niftytest.com.
**Home sampling, available in some areas. The days and times of appointments also vary by region.
NIFTY® is a registered trademark of BGI.
Clinical Validation Article: Noninvasive Prenatal testing for Trisomy 21, 18 and 13 – Clinical Experience from 146,958 Pregnancies.